Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) causes irreversible vision loss, and targeted anti-vascular endothelial growth factor (VEGF) therapy is now the most common and effective treatment. The aim of this meta-analysis is to discuss whether genetic polymorphism of ARMS2 A69S could confer susceptibility to advanced AMD with the response to anti-VEGF treatment. We performed a meta-analysis of relevant published studies selected through electronic databases. A total of 21 preferred studies regarding the association between ARMS2 gene and anti-VEGF treatment response in advanced AMD were generally included in the meta-analysis. The pooled results demonstrated that the carriage of G allele for ARMS2 A69S presented a better clinical prognosis for advanced AMD treated with anti-VEGF drugs (OR = 1.38, 95% CI = 1.13–1.69, p = 0.002). In addition, in the subgroup analysis based on ethnicity, ARMS2 polymorphisms were more likely to be a positive responder for East Asian patients (OR = 1.67, 95% CI = 1.29–2.16, p < 0.001). This meta-analysis through a series of rigorous methodology data demonstrated a significant association between ARMS2 A69S polymorphism and the anti-VEGF treatment response in advanced AMD, especially among East Asian population. Numerous well-designed, randomized, multicenter clinical trials with large sample size are required to validate the association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A degree of variability is likely due to the fact that results have emerged from various study types (observational and clinical), with heterogeneous patient populations treated with different anti-VEGF agents, with different dose regimens, and with response to treatment defined using different functional and anatomic end points.6,10,17”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [17]
In the citing paper
“The largest body of evidence on genetic variants associated with treatment response is related to ARMS2/HTRA1, CFH, and VEGFA,6,10,17–19 but even here results are conflicting.”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [17]
In the citing paper
“For example, meta-analyses have reported an association between anti-VEGF treatment response in nAMD and the A69S polymorphism (rs10490924) in the ARMS2 gene,20 the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the CFH gene,21,22 and the rs833061 polymorphism in the VEGFA gene.23”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [20]
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Mechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,021 · cited 1×
“Background Age-related macular degeneration (AMD) is a chronic, progressive condition presenting untreatable in up to 90% of patients, and is a major cause of irreversible blindness in the elderly individuals [1].”
BackgroundHTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Kanda, A., Chen, W., Othman, M., Branham, K. E. H., Brooks, M., Khanna, R., He, S., Lyons, R., Abecasis, G. R., & Swaroop, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703933104 · Cited by 441
The Prevalence of Age-Related Macular Degeneration in Asians
Kawasaki, R., Yasuda, M., Song, S. J., Chen, S.-J., Jonas, J. B., Wang, J. J., Mitchell, P., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.10.007 · Cited by 438
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA
Fritsche, L. G., Loenhardt, T., Janssen, A., Fisher, S. A., Rivera, A., Keilhauer, C. N., & Weber, B. H. F. (2008) · Nature Genetics · doi:10.1038/ng.170 · Cited by 400
Cited by
Disparities in Vision Health and Eye Care
Elam, A. R., Tseng, V. L., Rodriguez, T. M., Mike, E. V., Warren, A. K., Coleman, A. L., Aguwa, U., Alabiad, C., Briceno, C., Capo, H., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.07.010 · Cited by 208
Fu, Y., Zhang, Z., Webster, K. A., & Paulus, Y. M. (2024) · Biomolecules · doi:10.3390/biom14030252 · Cited by 45
Molecular Genetic Mechanisms in Age-Related Macular Degeneration
Shughoury, A., Sevgi, D. D., & Ciulla, T. A. (2022) · Genes · doi:10.3390/genes13071233 · Cited by 47
“Interestingly, while the ARMS2 rs10490924 G allele is associated with an increased risk of progression to advanced stages of disease [296], the G allele is also associated with a higher likelihood of MNV response to anti-VEGF therapy in patients who have progressed to neovascular disease [98,317,319–322], particularly…”
BackgroundGenetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113280 · Cited by 29
“ARMS2 A69S is a prognostic factor for an anti-VEGF response in wet AMD in the East Asian population, but not in the Caucasian or Middle Eastern group [48].”
BackgroundPhan, L. T., Broadhead, G., Hong, T., & Chang, A. (2021) · Clinical ophthalmology · doi:10.2147/opth.s205147 · Cited by 27
Metadata
- Authors
- Zhang, J., Liu, Z., Hu, S., & Qi, J.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Aier Eye Hospital Group (China) (CN)
- Army Medical University (CN)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2020-05-19
- Volume
- 64
- Issue
- 2
- Pages
- 192-204
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W3026686898
- Cited by
- 15
- References
- 43
- Citations by year
- 2026: 2 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 1
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- age-related macular degeneration, ARMS2, anti-VEGF therapy, treatment response, pharmacogenetics, genetic susceptibility, East Asian patients, ethnic differences
- MeSH terms
- Alleles, DNA, Genotype, Humans, Macular Degeneration, Pharmacogenetics, Proteins, Disease Management, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1159/000508738
- The paper
- Zhang, J., Liu, Z., Hu, S., & Qi, J. (2021). Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration. Ophthalmic Research. https://doi.org/10.1159/000508738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.